Status
Recruiting
Phase
Phase 4
Enrollment
24
Locations
1
Results
Not posted
Publications
0
Study summary
The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.
Interventions
DRUG
During endoscopic ultrasound (EUS), a dose of intravenous secretin (0.2 µg/kg) will be administered over the course of 1 minute to stimulate pancreatic ductal cells to secrete pancreas fluid. Duodenal fluid will be aspirated through the echoendoscope in 5 minute increments (5, 10, 15, and 20 minutes) after the secretin has been administered
Timeline
First posted
Dec 16, 2025
Study start
Mar 11, 2026
Primary completion
Mar 2027
Study completion
Mar 2028
Results posted
Not reported
Registry updated
Jul 7, 2026
Outcomes
Pancreatic Fluid Bicarbonate Composition
Time frame · 5, 10, 15, and 20-minutes post-secretin administration
A primary outcome will be the bicarbonate level (milliequivalent per liter) in the pancreatic fluid collected.
Pancreatic Fluid Sodium Composition
Time frame · 5, 10, 15, and 20-minutes post-secretin administration
A primary outcome will be the sodium level (milliequivalent per liter) in the pancreatic fluid collected.
Pancreatic Fluid Potassium Composition
Time frame · 5, 10, 15, and 20-minutes post-secretin administration
A primary outcome will be the potassium level (milliequivalent per liter) in the pancreatic fluid collected.
Pancreatic Fluid Chloride Composition
Time frame · 5, 10, 15, and 20-minutes post-secretin administration
A primary outcome will be the chloride level (milliequivalent per liter) in the pancreatic fluid collected.
Not reported in the indexed record.
Eligibility
Inclusion Criteria * Males or non-pregnant females * Age 18-80. * Participants must be in good health based on medical history (ASA Class 3 or below) * Participants must be willing and able to provide informed consent * Receiving an endoscopic ultrasound for a non-pancreatic indication Exclusion Criteria * History of any form of pancreatitis and/or other pancreatic diseases (e.g. pancreatic cysts, pancreatic masses). * History of inflammatory bowel disease * History of vagotomy. * History of surgically altered upper gastrointestinal anatomy (e.g. gastric bypass, Billroth I/II) * History of liver disease * Pregnant women or nursing mothers * Regular use of anticholinergics * \> 2 drinks of alcohol daily * Smokers (cigarette)
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Erasmus Medical Center · Liver Transplantation
Phase 1 / Phase 2
Enrolling by invitation
20
2026-06
Children's Hospital Medical Center, Cincinnati · Pancreatitis · Diabetes Mellitus
Phase 4
Enrolling by invitation
195
2026-03
University of California, Los Angeles · Anorexia in Adolescence
Not applicable
Recruiting
10
2026-02
M.D. Anderson Cancer Center · Pancreatitis
Not applicable
Recruiting
2,345
2025-10
Johns Hopkins University · Pancreas Cancer · Peutz-Jeghers Syndrome (PJS)
Phase 3
Recruiting
9,000
2025-10
The University of Texas Health Science Center at San Antonio · Post Bariatric Surgery · Gastric Bypass
Early Phase 1
Recruiting
200
2025-09
Adenocyte, LLC · IPMN, Pancreatic · Pancreas Cancer
Not applicable
Enrolling by invitation
500
2025-03
Charles University, Czech Republic · Pancreatic Adenocarcinoma · Pancreatic Cancer
Not applicable
Not yet recruiting
39
2025-02
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.